Sub-clinical doses of compounded semaglutide or tirzepatide for the metabolic and anti-inflammatory benefits of GLP-1 activation — without the heavy appetite shut-down or weight loss of a full-dose protocol. Built for lean optimizers.
Compounded medication is not FDA-approved. Sema $199/mo · Tirz $299/mo · HSA/FSA eligible.
LegitScript CertifiedHealthcare Merchant
Prescription only
✓ Licensed US providers✓ 2-3 day discreet shipping✓ Cancel anytime
LegitScript CertifiedHealthcare Merchant
Microdose GLP-1 protocols use sub-therapeutic doses of compounded semaglutide or tirzepatide — typically a fraction of the doses studied in pivotal weight-loss trials. The goal is metabolic optimization (insulin sensitivity, anti-inflammation, gentle appetite calibration), not significant weight loss. Prescribed by U.S.-licensed providers and dispensed by our licensed 503A pharmacy partners (Strive · Boothwyn · Absolute).
Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Sub-clinical (off-label) dosing is at provider discretion. Individual results vary.
Sema $199/mo · Tirz $299/mo · Same retail as full-dose · HSA/FSA eligible
Patients on microdose GLP-1 report an 87% improvement in how easy it is to maintain their goal physique.*
*Microdose-protocol patient-reported outcomes. Maintenance-ease score reflects average self-reported reduction in calorie tracking and food preoccupation. Individual results vary.
Microdose GLP-1 means using sub-clinical doses of compounded semaglutide or tirzepatide — well below the doses studied in the pivotal weight-loss trials of the FDA-approved branded preparations. The goal isn't significant weight loss. The goal is the metabolic and anti-inflammatory benefits of GLP-1 activation: improved insulin sensitivity, reduced visceral inflammation, gentler appetite regulation, better metabolic flexibility. Compounded preparations are not FDA-approved.
Built for lean optimizers, athletes, and biohackers — not patients with significant weight to lose.
Full-dose GLP-1 protocols are titrated to maximum tolerated dose for maximum weight loss. They produce intense appetite suppression that's hard to navigate if you need to eat enough to fuel training and recovery.
Microdose protocols use ~10-25% of full-dose to capture the metabolic upside while leaving your appetite mostly intact. Most lean operators describe it as "the GLP-1 mechanism without the side effects."
Microdose semaglutide ($199/mo): single GLP-1 receptor activation, gentlest profile, longest safety record. Best entry point for most optimization-focused patients.
Microdose tirzepatide ($299/mo): dual GIP + GLP-1 receptor activation, metabolic effects often more pronounced even at sub-clinical doses. Best for patients who want maximum metabolic flexibility.
Same retail as full-dose — we charge by molecule, not by milligram.
GLP-1 receptor activation has documented anti-inflammatory and insulin-sensitizing effects independent of weight loss. Sub-clinical dosing is an emerging clinical pattern in optimization medicine — there's strong mechanistic basis but fewer large-scale microdose-specific RCTs than full-dose.
Recent literature documents GLP-1's effects on visceral inflammation, cardiovascular markers, and metabolic flexibility at lower doses. Source: Drucker DJ, Cell Metabolism, 2018. Marso SP et al, NEJM, 2016 (LEADER).
10-25%
of full-dose titration
100%
FDA-approved weight-loss titration
Same molecule, same compounding standards — different titration. OPTML charges by molecule, not by dose, so microdose costs the same as full-dose.
No surprises, no upsells. Each shipment includes everything you need to administer safely at home, plus full clinical support.
STEP-1 (NEJM 2021, n=1,961) was the pivotal trial of FDA-approved branded semaglutide at the full 2.4 mg weekly dose. Microdose protocols use sub-clinical doses; the trial below is included as the science of the molecule, not a prediction of microdose outcomes.
Source: Wilding JPH et al. New England Journal of Medicine. STEP-1 Trial. 2021. Trial studied FDA-approved branded semaglutide at the 2.4 mg full dose; microdose patients receive sub-clinical doses and would not expect comparable weight loss.
Online assessment to first shipment in under a week. No in-person visits, no waiting rooms.
Start your free assessment →Answer a few questions about your health, weight history, and goals. Takes about 5 minutes online.
A U.S. licensed provider reviews your assessment and prescribes the right dose, if appropriate. You'll hear back from your provider.
If prescribed, your compounded semaglutide, syringes, and supplies ship discreetly in 2-3 days. Free 2-3 day shipping always.
Self-administer at home. Most patients report reduced cravings and steady weight loss within 2-4 weeks.
Message your provider anytime. Dose adjustments, refills, and side-effect questions handled in-app. Cancel anytime.
Question 1 of 12
Start microdose GLP-1 in 5 simple steps
Answer a few questions about your training, metabolic goals, and current physique — about 5 minutes.
No commitment. No insurance needed. See full eligibility & contraindications →
The data below reflects what patients on microdose protocols report subjectively (food noise, energy, metabolic markers). It is not the trajectory of full-dose STEP-1 weight loss. Sub-clinical microdosing aims at metabolic optimization, not body composition change. Individual results vary.
Most patients report reduced cravings and earlier fullness within the first two doses. Mild nausea is common; usually fades within a week.
Most microdose patients report reduced cravings and lower food preoccupation by week 4. Weight typically stable; the goal is metabolic, not scale.
By month three, providers often see improvements in fasting insulin, A1c trend, and inflammatory markers. Weight typically holds; body composition may quietly improve.
By month six, most report effortless physique maintenance and a quieter appetite signal. Long-term sub-clinical dosing is at provider discretion.
Context: Outcomes shown reflect microdose-protocol patient-reported observations. STEP-1 (Wilding JPH et al., NEJM 2021) studied FDA-approved branded semaglutide at the full 2.4 mg dose and produced an average 14.9% body-weight reduction over 68 weeks — microdose protocols use sub-clinical doses and are not expected to produce comparable weight loss. Compounded preparations are not FDA-approved.
Provider consult, compounded medication, and supplies, all included. Cancel anytime.
Provider-titrated microdose protocol of either compounded semaglutide or tirzepatide. Your monthly price stays the same as your dose evolves — same retail as full-dose, just dosed sub-clinically.
Microdose semaglutide. Tirzepatide $299/mo — same flat retail as full-dose.
Provider titrates your microdose protocol based on your response. Most operators see improved insulin sensitivity and quieter food noise within 4–6 weeks.
Your monthly price includes everything.
Physician consultation, prescription, and ongoing medical oversight. No hidden fees. No separate membership. Just your optml protocol.
Billed monthly. Cancel anytime.
Billed monthly. Cancel anytime.
Prescribed by board-certified U.S.-licensed clinicians
Licensed in all 50 states · Meet your care team
Free calculators and quizzes built around real clinical data. Use them as often as you want.
Goal date
When will you hit your goal weight?
GLP-1 cost
What you'll actually spend on GLP-1s this year
Savings
How much would you save with OPTML?
BMI
BMI & eligibility check
Match quiz
Find my protocol — match in 90 seconds
Deficit
Daily calorie deficit for your goal
TDEE
Total daily energy expenditure
BMR
Basal metabolic rate
Protein
Daily protein target for your goal
5-minute online consult. Provider review in 24 hours. First shipment in under a week.
LegitScript CertifiedHealthcare Merchant
5-minute online consult. Provider review in 24 hours. First shipment in under a week.